Davern Capital Partners »

Miragen Therapeutics shares owned by Davern Capital Partners

Quarter-by-quarter ownership of Miragen Therapeutics (VRDN) shares owned by Davern Capital Partners from 13F filings

Historical chart of Davern Capital Partners investment in Miragen Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Miragen Therapeutics held by Davern Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Miragen Therapeutics by Davern Capital Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $8.1M 262k 31.12

More positions owned by Davern Capital Partners

Pfizer (PFE)
Regeneron Pharmaceuticals (REGN)
Biontech Se Sponsored Ads (BNTX)
Royalty Pharma Shs Class A (RPRX)
Argenx Se Sponsored Adr (ARGX)
Legend Biotech Corp Sponsored Ads (LEGN)
Roivant Sciences SHS (ROIV)
Ionis Pharmaceuticals (IONS)
Natera (NTRA)
Eli Lilly & Co. (LLY)
Miragen Therapeutics (VRDN)
Mineralys Therapeutics (MLYS)
Cg Oncology (CGON)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Davern Capital Partners

Top funds holding Miragen Therapeutics

FMR
Vanguard Group
BlackRock
Deep Track Capital
Kynam Capital Management
VR Adviser
Fairmount Funds Management
Commodore Capital
Tang Capital Management
Paradigm Biocapital Advisors
State Street Corporation
Novo A/S
Maverick Capital
Geode Capital Management
Eversept Partners

View all funds holding Miragen Therapeutics